Outcome of Board Meeting

November 05, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai – 400001 Bandra (East), Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub.: Outcome of the Board Meeting of the Company. Ref.: 1. Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”); 2. Our intimation dated October 28, 2026 Dear Sir / Madam, With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Thursday, November 05, 2026, have inter alia considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter and half year ended September 30, 2026 (“unaudited Financial Results”). Enclosed are the Unaudited Financial Results along with Limited Review Reports for your records. (Pursuant to Regulation 47 of the SEBI Listing Regulations, extract of these results will be published in newspapers). The meeting commenced at 04:30 p.m. and concluded at 5.30 p.m. The Trading Window for dealing in Company’s securities shall remain closed until 48 hours from this announcement. The above information is being made available on website of the Company i.e. https://investor.symbiotec.com/financials?tab=results Thanking You. Sincerely, For Symbiotec Pharmalab Limited Salil Jain Company Secretary and Compliance Officer Membership No. A41610 Encl: As above Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 Anilkumar Digitally signed by Anilkumar Chandubhai C Dh Na : n cd nu =b Ah na ili k J uo mb aa rn Cpu ht ara ndubhai Jobanputra J Do ab tea :n 2p 0u 2tr 6a ., 1 c 1= .0IN 5, 1o 9= :P 04e :r 0s 1o n +a 0l 5'30' Symbiotec Pharmalab Limited Corporate Identity Number (CIN):U24232MP2002PLC015293 Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India Email: investorrelations@symbiotec.com Website: https://symbiotec.com Statement of unaudited consolidated financial results for the Quarter ended and Half year ended September 30,2026 (Rs. in Million) Quarter ended Half Year ended Year ended Particulars September June 30,2026 September September September March 31,2026 30,2026 (Unaudited) 30,2025 30,2026 30,2025 (Audited) (Unaudited) (Refer Note 4) (Refer Note 3) (Unaudited) (Refer Note 3) (Refer Note 4) Income Revenue from operations 2,799.28 2,181.50 1,955.15 4,980.78 3,986.87 8,691.49 Other income 1.12 3.38 1.60 4.50 28.01 31.09 Total income (A) 2,800.40 2,184.88 1,956.75 4,985.28 4,014.88 8,722.58 Expenses Cost of raw materials, packing material and consumables consumed 796.16 755.59 701.00 1,551.75 1,474.27 3,154.64 Employee benefit expenses 469.58 464.21 376.96 933.79 728.37 1,543.39 Finance costs 57.04 61.79 63.86 118.83 116.63 253.27 Depreciation and amortisation expense 218.74 218.24 105.88 436.98 210.96 532.83 Other expenses 618.44 509.73 374.35 1,128.17 701.73 1,614.89 Total expenses (B) 2,159.96 2,009.56 1,622.05 4,169.52 3,231.96 7,099.02 Profit before exceptional item and tax (C= (A-B)) 640.44 175.32 334.70 815.76 782.92 1,623.56 Exceptional item (D) Impact of New wages code on Gratuity and Leave encashment - - - - - 89.93 Profit before tax (E=(C-D)) 640.44 175.32 334.70 815.76 782.92 1,533.63 Income Tax expense Current tax Charge/(Credit) 169.42 160.20 145.06 329.62 305.17 593.75 Adjustment of tax relating to earlier period/year Charge/(Credit) - - - - - 1.96 Deferred Tax Charge/(Credit) (46.16) (125.49) (2.54) (171.65) (13.63) (140.04) Deferred Tax relating to Exceptional items Charge/(Credit) - - - - (21.07) Total Income tax expense/(credit) (F) 123.26 34.71 142.52 157.97 291.54 434.60 Net Profit for the period/year (G= (E-F)) 517.18 140.61 192.18 657.79 491.38 1,099.03 Other comprehensive income, net of income tax Items that will be reclassified to profit and loss in subsequent period Exchange difference on translation of foreign operations (1.24) 1.53 0.02 0.29 0.50 (8.10) Items that will not be reclassified to profit and loss in subsequent period Re-measurements gains/ (losses) on defined benefit plans 10.77 (1.11) 0.74 9.66 (1.31) (3.72) Income tax effect on above (2.66) 0.24 (0.16) (2.42) 0.33 0.66 Total (H) 8.11 (0.87) 0.58 7.24 (0.98) (3.06) Total other comprehensive Income/(loss), net of income tax (I) 6.87 0.66 0.60 7.53 (0.48) (11.16) Total comprehensive income for the period/year (J)=(G+I) 524.05 141.27 192.78 665.32 490.90 1,087.87 Total comprehensive income for the period/year attributable to: Owners of the Parent Company 524.04 141.21 192.79 665.25 490.86 1,087.38 Non-controlling interests 0.01 0.06 (0.01) 0.07 0.04 0.49 Net Profit attributable to: Owners of the Parent Company 517.26 140.56 192.19 657.82 491.37 1,098.82 Non-controlling interests (0.08) 0.05 (0.01) (0.03) 0.01 0.21 Other comprehensive Income/(loss) attributable to: Owners of the Parent Company 6.78 0.65 0.59 7.4 (0.51) (11.44) Non-controlling interests 0.09 0.01 0.01 0.10 0.03 0.28 Paid-up equity share capital (Face value of Rs 2/- per share) 128.51 125.47 125.47 128.51 125.47 125.47 Other Equity 11,371.83 Earnings per share (of face value Rs. 2/- per share) [not annualised] Basic (in Rs.) 8.20 2 .24 3.45 10.44 8.82 19.10 Diluted (in Rs.) 8.20 2 .24 3.43 10.44 8.77 19.00 Symbiotec Pharmalab Limited Corporate Identity Number (CIN):U24232MP2002PLC015293 Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India Email: investorrelations@symbiotec.com Website: https://symbiotec.com Unaudited Consolidated Statement of Assets and Liabilities (Rs. in Million) As at As at Particulars September 30, 2026 March 31, 2026 Unaudited Audited Assets Non-current assets Property, plant and equipment 10,549.90 10,843.87 Capital work-in-progress 1,380.90 644.81 Investment properties 356.74 359.38 Financial assets (i) Investments 44.84 44.84 (ii) Other financial assets 201.28 89.43 Deferred tax assets (net) 111.05 - Income tax assets (net) 0.34 0.21 Other non-current assets 1,272.18 969.94 Total non-current assets (A) 13,917.23 12,952.48 Current assets Inventories 3,033.58 2,368.81 Financial assets (i) Trade receivables 2,682.77 1,975.98 (ii) Cash and cash equivalents 216.56 100.40 (iii) Bank Balances other than cash and cash equivalents 1.10 0.85 (iv) Other financial assets 267.86 272.34 Other current assets 320.05 137.06 Total current assets (B) 6,521.92 4,855.44 Total assets (C)=(A+B) 20,439.15 17,807.92 Equity and Liabilities Equity Equity share capital 128.51 125.47 Other equity 13,480.90 11,371.83 Equity attributable to the equity shareholders of the parent company 13,609.41 11,497.30 Non Controlling Interest (1.33) (1.40) Total equity (D) 13,608.08 11,495.90 Liabilities Non-current liabilities Financial Liabilities (i) Borrowings 1,622.28 684.13 (ii) Lease liabilities 22.34 20.51 (iii) Other financial liabilities 171.07 57.87 Provisions 217.41 215.73 Deferred tax liabilities (net) - 58.13 Total non-current liabilities (E) 2,033.10 1,036.37 Current liabilities Financial liabilities (i) Borrowings 1,709.16 3,195.01 (ii) Lease liabilities 5.32 10.25 (iii) Trade payables Total outstanding dues of micro enterprises and small enterprises 117.64 50.81 Total outstanding dues of creditors other than micro enterprises and small enterprises 1,609.13 1,332.46 (iv) Other financial liabilities 752.72 344.43 Other current liabilities 400.41 197.37 Provisions 67.25 65.86 Current tax liabilities (net) 136.34 79.46 Total current liabilities (F) 4,797.97 5,275.65 Total liabilities (G)=(E+F) 6,831.07 6,312.02 Total equity and liabilities (H)= (D+G) 20,439.15 17,807.92 Sym [Showing first 8,000 characters — download PDF for full document]